 |
|
|
| |
Impact of UGT Induction by Rifampin and Rifabutin on Cabotegravir Long-Acting Pharmacokinetics for HIV Pre-exposure Prophylaxis (PrEP) using Population Pharmacokinetic Modeling and Simulation
|
| |
| |
HIVR4P 2021 (Virtual event); 27-28 January & 3-4 February 2021
Reported by Jules Levin
Kelong Han, 1 Mark Baker, 2 David Margolis, 2 William Spreen, 2 Susan L. Ford 3
1GlaxoSmithKline, Collegeville, PA; 2ViiV Healthcare, Research Triangle Park, NC; 3GlaxoSmithKline, Research Triangle Park, NC
|
| |
|
|
|
|
|
